Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia

In acute myeloid leukemia (AML), TP53 mutations and dysregulation of wild-type p53 is common and supports an MDM2 antagonist as a therapy. RO6839921 is an inactive pegylated prodrug of the oral MDM2 antagonist idasanutlin (active principle [AP]) that allows for IV administration. This phase 1 monoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Uy, Geoffrey L., Assouline, Sarit, Young, Anne-Marie, Blotner, Steven, Higgins, Brian, Chen, Lin-Chi, Yee, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497671/
https://www.ncbi.nlm.nih.gov/pubmed/32020437
http://dx.doi.org/10.1007/s10637-020-00907-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497671/
https://www.ncbi.nlm.nih.gov/pubmed/32020437
http://dx.doi.org/10.1007/s10637-020-00907-4

Ejemplares similares